Ducharme Lori J, Roman Paul M
Institute for Behavioral Research, University of Georgia, Athens, GA 30602-2401, USA.
J Subst Abuse Treat. 2009 Jul;37(1):90-4. doi: 10.1016/j.jsat.2008.09.003. Epub 2008 Nov 11.
As the Clinical Trials Network (CTN) begins to focus efforts on disseminating the results of its research studies to the addiction treatment field, it is important to begin to assess the capacity of programs outside the CTN to integrate with fidelity these endorsed treatment practices. To date, no data exist to assess the representativeness of opioid treatment programs (OTPs) participating in the CTN, nor potential barriers to the effective diffusion of practices aimed at the treatment of opioid-dependent patients, including buprenorphine. Using data obtained from OTPs within the CTN (n = 49) and a sample drawn from the population of U.S. OTPs (n = 50), this study compares the two groups on their organizational, clinical, and client characteristics, as well as their adoption of buprenorphine. The study finds that the populations differ significantly on numerous variables but that structural characteristics appear more predictive of buprenorphine adoption than either staff or caseload differences. Implications for studying the diffusion and implementation of evidence-based research findings are discussed.
随着临床试验网络（CTN）开始将工作重点转向向成瘾治疗领域传播其研究结果，开始评估CTN之外的项目忠实地整合这些认可的治疗方法的能力变得很重要。迄今为止，尚无数据可用于评估参与CTN的阿片类药物治疗项目（OTP）的代表性，也没有数据可用于评估旨在治疗阿片类药物依赖患者（包括丁丙诺啡）的治疗方法有效传播的潜在障碍。本研究使用从CTN内的OTP获得的数据（n = 49）以及从美国OTP人群中抽取的样本（n = 50），比较了两组在组织、临床和客户特征以及丁丙诺啡采用情况方面的差异。研究发现，两组人群在众多变量上存在显著差异，但结构特征似乎比工作人员或病例数量差异更能预测丁丙诺啡的采用情况。本文还讨论了对研究循证研究结果的传播和实施的启示。
